Mucopolysaccharidosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Mucopolysaccharidosis stocks.

Mucopolysaccharidosis Stocks Recent News

Date Stock Title
May 7 BMRN Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
May 6 BMRN Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
May 6 BMRN 5 Biotech Stocks Worth Adding to Your Portfolio in 2024
May 6 BMRN BioMarin touts new data on Voxzogo for additional indications
May 4 BMRN New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
May 4 RARE Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
May 4 RARE Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
May 3 RARE Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
May 3 RARE Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
May 3 RARE Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
May 2 RARE Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
May 2 RARE Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64M
May 2 RARE Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
May 1 RARE Ultragenyx Pharmaceutical Q1 2024 Earnings Preview
May 1 RGNX REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
Apr 30 RARE Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
Mucopolysaccharidosis

Mucopolysaccharidoses are a group of metabolic disorders caused by the absence or malfunctioning of lysosomal enzymes needed to break down molecules called glycosaminoglycans (GAGs). These long chains of sugar carbohydrates occur within the cells that help build bone, cartilage, tendons, corneas, skin and connective tissue. GAGs (formerly called mucopolysaccharides) are also found in the fluids that lubricate joints.
Individuals with mucopolysaccharidosis either do not produce enough of one of the eleven enzymes required to break down these sugar chains into simpler molecules, or they produce enzymes that do not work properly. Over time, these GAGs collect in the cells, blood and connective tissues. The result is permanent, progressive cellular damage which affects appearance, physical abilities, organ and system functioning.
The mucopolysaccharidoses are part of the lysosomal storage disease family, a group of more than 40 genetic disorders that result when the lysosome organelle in animal cells malfunctions. The lysosome can be thought of as the cell's recycling center because it processes unwanted material into other substances that the cell can utilize. Lysosomes break down this unwanted matter via enzymes, highly specialized proteins essential for survival. Lysosomal disorders like mucopolysaccharidosis are triggered when a particular enzyme exists in too small an amount or is missing altogether.

Browse All Tags